GeneFab Announces Two Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2024
April 22, 2024 16:30 ET
|
GeneFab, LLC
– Two accepted abstracts highlight innovative methods for gene expression regulation – – GeneFab’s synthetic biology capabilities and Advanced Therapies offerings enable development of affordable...
CNL FINANCIAL GROUP ANNOUNCES NEW NATIONAL SALES DIRECTOR
April 22, 2024 16:30 ET
|
CNL Strategic Capital
Orlando, Fla., April 22, 2024 (GLOBE NEWSWIRE) -- News Release For information contact:Colleen JohnsonSenior Vice President, Marketing and CommunicationsCNL Financial Group407-650-1223 CNL...
Tessera Therapeutics to Present New Data Across Preclinical Programs for its Gene Writing™ and Delivery Platforms at the American Society of Gene and Cell Therapy 27th Annual Meeting
April 22, 2024 16:30 ET
|
Tessera Therapeutics
SOMERVILLE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Tessera Therapeutics, a biotechnology company pioneering a new approach to genome engineering through the development of its Gene Writing™ and...
BIO-key International, Inc. Receives Notice of Non-Compliance from Nasdaq
April 22, 2024 16:30 ET
|
BIO-key International, Inc.
BIO-key International, Inc. Received Notice of Non-Compliance from Nasdaq regarding filing all required periodic financial reports with the SEC.
Excision BioTherapeutics Announces Oral Presentation Highlighting Positive Data from its HBV Program, EBT-107, at the Upcoming ASGCT 2024 Annual Meeting
April 22, 2024 16:30 ET
|
Excision BioTherapeutics
SAN FRANCISCO, April 22, 2024 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc. (“Excision”, the “Company”), a clinical-stage biotechnology company developing CRISPR-based therapies to cure serious...
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
April 22, 2024 16:30 ET
|
Fate Therapeutics, Inc.
Key Therapeutic Mechanisms of Clinical Activity for Autoimmune Diseases, including B cell Depletion, Tissue Infiltration and Immune Reconstitution Data, from Phase 1 Study of FT819 in Relapsed /...
CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
April 22, 2024 16:30 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, April 22, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
Cellectis présente de nouveaux procédés d’éditions par TALEN® permettant une insertion et une correction du génome très efficaces dans les cellules souches progénitrices et hématopoïétiques (CSPHs)
April 22, 2024 16:30 ET
|
Cellectis Inc.
Cette nouvelle approche d'édition pourrait être utilisée pour développer de nouveaux traitements pour les maladies métaboliques et neurologiquesL'utilisation d'ADN simple brin circulaire associée à...
Skynet Trading receives backing from Saxo Bank Co-Founder Lars Seier Christensen and Edessa Capital
April 22, 2024 16:30 ET
|
Skynet Trading
Hong Kong, April 22, 2024 (GLOBE NEWSWIRE) -- Skynet Trading Limited, a leading firm in digital assets trading and algorithmic software development, has announced a notable private transaction with...
Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
April 22, 2024 16:30 ET
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it will...